andecaliximab (GS-5745) / Gilead  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
andecaliximab (GS-5745) / Gilead
NCT02759562 / 2015-002192-23: Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis

Terminated
2b
6
Europe, RoW
Andecaliximab, GS-5745, Placebo
Gilead Sciences
Cystic Fibrosis
07/17
07/17
NCT02405442 / 2015-001249-10: Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

Terminated
2
187
Canada, US, Europe, RoW
Andecaliximab, GS-5745, Placebo
Gilead Sciences
Crohn's Disease
11/16
12/16
RA POC, NCT02862574 / 2016-000897-39: Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Terminated
2
15
US
Andecaliximab, GS-5745, Placebo, Methotrexate, TNF Inhibitor
Gilead Sciences
Rheumatoid Arthritis
06/17
08/17
NCT02864381 / 2016-001402-41: Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Checkmark Completion of P2 trial in combination with nivolumab (andecaliximab discontinued)
Nov 2018 - Nov 2018: Completion of P2 trial in combination with nivolumab (andecaliximab discontinued)
Checkmark In adults with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (andecaliximab discontinued)
Nov 2018 - Nov 2018: In adults with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (andecaliximab discontinued)
Completed
2
144
Europe, US, RoW
Andecaliximab, GS-5745, Nivolumab
Gilead Sciences
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
11/17
08/19

Download Options